Freeline Therapeutics Holdings plc (FRLN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Stevenage, United Kingdom. The current CEO is Michael J. Parini.
FRLN has IPO date of 2020-08-07, 152 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $28.28M.
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
